7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carbaldehyde | 909718-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carbaldehyde
• 英文别名: 2-trifluoromethyl-4-formyl-7-methoxy-pyrazolo[1,5-a]pyridine
• CAS: 909718-83-8
• 化学式: C₁₀H₇F₃N₂O₂
• 分子量: 244.173
• InChiKey: NTXWRBUSBGHYQS-UHFFFAOYSA-N

物化性质

• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carbaldehyde 在 chromium(VI) oxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 、 硫酸 、 丙酮 为溶剂， 反应 3.55h， 生成 2-(3,5-dichloropyridin-4-yl)-1-[7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl]ethanone
  参考文献：
  名称：

  Phosphodiesterase inhibitors. Part 6: Design, synthesis, and structure–activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity

  摘要：

  We previously identified KCA-1490 [(-)-6-(7-methoxy-2-trifluoromethyl-pyrazolo[1,5-alpha] pyridin-4-yl)-5- methyl-4,5-dihydro-3-(2H)-pyridazinone], a dual PDE3/4 inhibitor. In the present study, we found highly potent selective PDE4 inhibitors derived from the structure of KCA-1490. Among them, N-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(trifluoromethyl) pyrazolo[1,5-alpha] pyridine-4-carboxamide (2 alpha) had good anti-inflammatory effects in an animal model. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.069
• 作为产物：
  描述：

  (6-甲氧基吡啶-3-基)甲醇 在 manganese(IV) oxide 、 potassium carbonate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 氯仿 、 水 、 N,N-二甲基甲酰胺 、 邻二氯苯 为溶剂， 反应 44.0h， 生成 7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carbaldehyde
  参考文献：
  名称：

  Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure–activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

  摘要：

  (-)-6-(7-甲氧基-2-三氟甲基嘌唑并[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3-(2H)-吡啶嗪酮（KCA-1490）是一种 dual PDE3/4抑制剂，具有强大的联合支气管扩张和抗炎活性。对KCA-1490中嘌唑并[1,5-a]吡啶核心的潜在双环杂芳香族替换基团的调查已确定了4-甲氧基-2-(三氟甲基)苯并[d]噻唑-7-基和8-甲氧基-2-(三氟甲基)喹啉-5-基类似物作为 dual PDE3/4抑制剂，它们能有力地抑制组胺引起的支气管收缩，并在体内表现出抗炎活性。© 2012 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.bmc.2012.01.033

文献信息

• Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient
  申请人：Kohno Yasushi

  公开号：US20080207902A1

  公开（公告）日：2008-08-28

  Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).

  新型吡唑吡啶-4-基吡啉酮衍生物作为磷酸二酯酶抑制剂，并且是用于制药产品的有用化合物。具体来说，本发明的化合物是由以下一般式（1）表示的吡唑吡啶-4-基吡啉酮衍生物（例如：6-(2-乙基-7-甲氧基吡唑并[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3(2H)-吡啉酮）。
• An Improved Method for Synthesis of 4,4-Dimethylpyrazolone and Application to Dihydropyridazinone Ring Formation
  作者：Koji Ochiai、Akihiko Kojima、Yasushi Kohno

  DOI：10.1248/cpb.60.267

  日期：——

  An improved method for 4,4-dimethylpyrazolone synthesis with t-butylcarbazate was described. The applicability of this method to dihydropyridazinone formation was demonstrated. This method is useful for suppressing the side reaction caused by the high nucleophilicity of hydrazine.

  描述了一种用氨基甲酸叔丁酯合成4,4-二甲基吡唑酮的改进方法。证明了该方法对二氢哒嗪酮形成的适用性。该方法对于抑制由肼的高亲核性引起的副反应是有用的。
• Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient
  申请人：Kohno Yasushi

  公开号：US20090318385A1

  公开（公告）日：2009-12-24

  A novel pyrazolopyridine derivative is provided which is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine derivative is represented by the following general formula (1): [wherein R 1 is a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like, R 2 is an optionally substituted alkyl group having 1 to 6 carbon atoms or the like, R 5 and R 6 are independently a hydrogen atom or a halogen atom, R 13 is a hydrogen atom or a halogen atom, n is 0 or 1, is a single or double bond, R 3 is a hydrogen atom, a hydroxyl group, or the like, and R 4 is a hydrogen atom, a phenyl group, or the like] or a pharmaceutically acceptable salt thereof, and a hydrate thereof.

  提供了一种新的吡唑吡啶衍生物，其可用作具有磷酸二酯酶抑制活性的药物。该吡唑吡啶衍生物由以下通式（1）表示：[其中，R1是氢原子、1至6个碳原子的可选取代烷基或类似物，R2是1至6个碳原子的可选取代烷基或类似物，R5和R6独立地是氢原子或卤素原子，R13是氢原子或卤素原子，n为0或1，为单键或双键，R3是氢原子、羟基或类似物，R4是氢原子、苯基或类似物]或其药学上可接受的盐和水合物。
• Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
  申请人：Kohno Yasushi

  公开号：US20100056791A1

  公开（公告）日：2010-03-04

  A novel pyrazolopyridine carboxamide derivative is provided that is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine carboxamide derivative is represented by the following general formula (1): (Example: 2-ethyl-7-methoxypyrazolo[1,5-a]pyridine-4-carboxylic acid (3,5-dichloropyridin-4-yl)amide).

  提供了一种新型的吡唑吡啶羧酰胺衍生物，其可用作具有磷酸二酯酶抑制活性的药物。该吡唑吡啶羧酰胺衍生物由以下通式（1）表示：（例如：2-乙基-7-甲氧基吡唑并[1,5-a]吡啶-4-羧酸（3,5-二氯吡啶-4-基）酰胺）。
• Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US07763617B2

  公开（公告）日：2010-07-27

  Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).

  小说嘧唑吡啶-4-基吡啶酮衍生物作为磷酸二酯酶抑制剂，并且是在制药产品中使用的有用化合物。具体而言，本发明的化合物是由以下一般式(1)表示的嘧唑吡啶-4-基吡啶酮衍生物:(例子: 6-(2-乙基-7-甲氧基嘧唑[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3(2H)-吡啶酮)。